DGS Capital Management LLC Buys 149 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

DGS Capital Management LLC boosted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 20.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 867 shares of the medical equipment provider’s stock after purchasing an additional 149 shares during the quarter. DGS Capital Management LLC’s holdings in Intuitive Surgical were worth $292,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Keel Point LLC boosted its position in Intuitive Surgical by 3.6% during the fourth quarter. Keel Point LLC now owns 1,258 shares of the medical equipment provider’s stock worth $424,000 after purchasing an additional 44 shares during the period. Sentry Investment Management LLC boosted its position in Intuitive Surgical by 62.0% during the fourth quarter. Sentry Investment Management LLC now owns 3,303 shares of the medical equipment provider’s stock worth $1,114,000 after purchasing an additional 1,264 shares during the period. Mackenzie Financial Corp lifted its holdings in shares of Intuitive Surgical by 15.7% during the fourth quarter. Mackenzie Financial Corp now owns 289,405 shares of the medical equipment provider’s stock worth $97,634,000 after buying an additional 39,238 shares during the last quarter. Strs Ohio lifted its holdings in shares of Intuitive Surgical by 9.3% during the fourth quarter. Strs Ohio now owns 178,655 shares of the medical equipment provider’s stock worth $60,271,000 after buying an additional 15,233 shares during the last quarter. Finally, Kades & Cheifetz LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter worth approximately $230,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of ISRG stock opened at $378.55 on Wednesday. The stock’s fifty day moving average is $387.90 and its 200-day moving average is $342.17. The stock has a market capitalization of $134.18 billion, a PE ratio of 75.26, a PEG ratio of 5.86 and a beta of 1.36. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Tuesday, January 23rd. The medical equipment provider reported $1.60 EPS for the quarter, topping the consensus estimate of $1.48 by $0.12. The company had revenue of $1.93 billion for the quarter, compared to analysts’ expectations of $1.89 billion. Intuitive Surgical had a return on equity of 13.11% and a net margin of 25.24%. The business’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.91 earnings per share. As a group, analysts forecast that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current fiscal year.

Insider Activity at Intuitive Surgical

In related news, VP Fredrik Widman sold 5,041 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the completion of the sale, the vice president now directly owns 110 shares of the company’s stock, valued at $43,677.70. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Alan J. Levy sold 2,000 shares of Intuitive Surgical stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $370.20, for a total transaction of $740,400.00. Following the transaction, the director now owns 25,319 shares of the company’s stock, valued at approximately $9,373,093.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Fredrik Widman sold 5,041 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the completion of the sale, the vice president now directly owns 110 shares of the company’s stock, valued at approximately $43,677.70. The disclosure for this sale can be found here. Insiders have sold a total of 248,418 shares of company stock worth $95,927,097 over the last 90 days. Insiders own 0.80% of the company’s stock.

Analysts Set New Price Targets

ISRG has been the subject of a number of research analyst reports. Mizuho upped their price target on Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. Raymond James upped their price target on Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a report on Thursday, January 25th. Piper Sandler upped their target price on Intuitive Surgical from $325.00 to $425.00 and gave the company an “overweight” rating in a research note on Wednesday, January 24th. Wells Fargo & Company upped their target price on Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a research note on Friday, January 19th. Finally, Citigroup upped their target price on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $375.70.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.